Clinical trials: Lung Cancer Non-Small Cell Cancer (NSCLC)
Non Small Cell Lung Cancer
Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC
Although phase III studies have confirmed the efficacy and safety of perioperative immunotherapy plus chemotherapy for resectable NSCLC, there remains room for improvement in both short-term efficacy and long-term survival.
- Trial name
- NCT07567326
- Testing
- Adebrelimab, Retlirafusp alfa, Recaticimab and chemotherapy
- Volunteers
- 78 people
- Sponsor
- Peking University Cancer Hospital & Institute
Locally Advanced Non-Small Cell Lung Cancer
Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer
The purpose of this study is to determine the effectiveness of proton beam radiotherapy combined with chemotherapy for treatment of locally advanced non-small cell lung cancer.
- Trial name
- NCT00614484
- Testing
- Proton Radiation Therapy, Taxol, Carboplatin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Loma Linda University
Lung Cancer
Study on Systemic and Airway Cytokines and Oxidative Stress in Lung Cancer Patients Undergoing Surgery
Lung cancer has remained as the top cancer killer in Hong Kong. Even for early resectable stage of lung cancer, only around 60-70% of patients can survive for 5 years after operation, mostly related to disease recurrence.
- Trial name
- NCT00956852
- Where
- Hong Kong
- Volunteers
- 45 people
- Sponsor
- The University of Hong Kong
Non-Squamous Non-Small Cell Lung Cancer
AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung
This prospective observational study will evaluate the efficacy and safety of first-line Avastin (bevacizumab) in combination with platinum-based chemotherapy in different age groups (<60, 60-69, 70-79, >80 years) in patients…
- Trial name
- NCT01827852
- Where
- Germany
- Volunteers
- 1,107 people
- Sponsor
- Hoffmann-La Roche
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)
This is a prospective open label, controlled, randomized study to test the safety and efficacy of active specific immunotherapy with tecemotide (L-BLP25) for the treatment of subjects with Stage IIIB or Stage IV non-small cell…
- Trial name
- NCT00157209
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Best Supportive Care (BSC)
- Where
- Germany
- Volunteers
- 171 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Lung Cancer
Celecoxib or Observation After Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00274898
- Testing
- celecoxib, docetaxel, adjuvant therapy
- Where
- 15 sites in France
- Volunteers
- 80 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Non-small Cell Lung Cancer, Gastric Cancer
Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor
Natural killer T (NKT) cells are a unique subset of lymphocytes that present a mixed T-NK phenotype. Our hypothesis is that Natural killer T cells may decrease the tumor burden and improve overall survival.
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT02562963
- Testing
- natural killer T cell
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Minghui Zhang
Non-Small Cell Lung Cancer
GEMINI-NSCLC: NSCLC Biomarker Study
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care…
- Trial name
- NCT05236114
- Testing
- Observation
- Where
- 58 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Tempus AI
Non-Small Cell Lung Cancer
Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer
To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.
- Trial name
- NCT00283478
- Testing
- Iscar Quercus, Gemcitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kentuckiana Cancer Institute
Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
The goal of this clinical trial is to evaluate the efficacy and safety of albumin-bound paclitaxel-lenvatinib-pembrolizumab in advanced nonsquamous NSCLC patients after progression to first-line anti-PD-1/L1 inhibitor with…
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
- Trial name
- NCT06028633
- Testing
- pembrolizumab, lenvatinib, albumin-bound paclitaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Peking University First Hospital
Unresectable Stage III NSCLC
Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC
The chemoradiotherapy (CCRT) is still a standard treatment for the unresectabl stage III NSCLC.However, prognosis following this treatment is generally poor, with 5-year survival of 15-20%.
- Trial name
- R-helper (NCT04161352)
- Volunteers
- 500 people
- Sponsor
- Zhejiang Cancer Hospital
Lung Cancer
Studying Patterns, Causes, and Control of Disease in Patients With Lung Cancer in the North Trent (England) Region
RATIONALE: Gathering information about genetic and environmental factors from patients with lung cancer and their partners and first-degree relatives may help doctors learn more about the disease.
- Trial name
- NCT00693836
- Testing
- genetic linkage analysis, loss of heterozygosity analysis, mutation analysis
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Cancer Research Centre at Weston Park Hospital
Carcinoma, Nonsquamous Non-small-cell Lung
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1.
- Trial name
- NCT03976323
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 178 sites in United States, Argentina and 18 more
- Volunteers
- 1,003 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
[18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer.
[18F]F-AraG is a promising tracer to image activated T-cells with positron emission tomography (PET). The aim of the ATTAIN trial is to investigate the pharmacokinetic characteristics of this novel tracer by performing a full…
- Trial name
- ATTAIN (NCT05157659)
- Testing
- [18F]F-AraG PET-scan
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Amsterdam UMC, location VUmc
Non-Small Cell Lung Cancer
Role of PET CT in Determining Target Volumes in Radiation Therapy for Lung Cancer
Radiation therapy is an important part of the treatment for lung cancer when treatment intent is for cure. Radiation is a local modality of treatment, that is, it only treats the area that the radiation can target.
- Trial name
- NCT00221169
- Testing
- Surgical resection
- Where
- 2 sites in Canada
- Volunteers
- 31 people
- Sponsor
- Toronto Sunnybrook Regional Cancer Centre
Radiation Pneumonitis
The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia
Radiation pneumonitis (RP) is a common complication of radiotherapy for thoracic tumors, and the incidence rate of grade 2 or above RP is 20% -40%; The use of antibiotics after secondary bacterial infection due to radiation…
- Trial name
- NCT06079931
- Testing
- Babaodan Capsule
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Non-Small Cell Lung Cancer Metastatic
Almonertinib With Chemotherapy in mEGFR NSCLC
The reason for the study is to find out if an experimental combination of an oral medication called Almonertinib when used in combination with chemotherapy is more effective for the treatment of locally advanced or metastatic…
- Trial name
- NCT04646824
- Testing
- Almonertinib Pemetrexed/Cisplatin
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Lung Cancer
A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer
This is an open-label multi-center Phase 2 efficacy and safety study of crizotinib in East Asian patients with advanced Non-Squamous NSCLC harboring a translocation or inversion event involving the ALK gene locus who have…
- Trial name
- NCT01500824
- Testing
- Crizotinib
- Sponsor
- Pfizer
Cancer
Curative Study of Chinese Traditional Medicine to Treat Lung Cancer
The purpose of this study is to observe the efficacy of chemotherapy combined with Chinese patent drugs for patients with advanced non-small-cell lung cancer, also to evaluate the adverse reaction and the reliability.
- Trial name
- TCM (NCT02777788)
- Testing
- JinFuKang, XingZaoRuanJian, pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin
- Volunteers
- 120 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer)
Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
This study is being done to test whether bright light therapy can be used to synchronize patients' circadian rhythms and allow ICB (immune-checkpoint blockade) therapy to be administered at a time in the circadian rhythm that…
- Trial name
- IIT BLT (NCT07661966)
- Testing
- Bright Light Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Weill Medical College of Cornell University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.